India rejects ARV patent applications, saving “countless lives”


“This is fantastic news that will save countless lives in the developing world – we can now continue to access these two very effective ARVs at an affordable price,” James Kamau, coordinator of the Kenya Treatment Access Movement, told IRIN/PlusNews. Many developing countries had held off ordering generic tenofovir from Indian companies in case the patent applications were approved.
India’s patent office rejected applications filed by US-based manufacturer Gilead Sciences Inc for tenofovir, and Tibotec Pharmaceuticals Inc, a subsidiary of pharmaceutical giant Johnson & Johnson, for darunavir.
Cipla, the Indian generic drug maker, and several civil society groups argued that the patent applications did not meet the criteria in section 3(d) of India’s Patents Act, which include proving the “enhanced efficacy” of new uses or new forms of existing products.
Indian law recognised few patent restraints before the country joined the World Trade Organisation (WTO) in 2005, allowing it to develop one of the world’s largest generic drug manufacturing industries.
India is now bound by the WTO’s Trade Related Aspects of Intellectual Property Rights (TRIPS), which strengthens the intellectual property rights of pharmaceutical firms, and it has had to revise its patent laws to align them with WTO standards.
More Indian manufacturers will also be able to produce the generics, leading to further competition and lower costs. In June, Brazil also rejected a patent application by Gilead for tenofovir.
The UN World Health Organization recommends tenofovir for use in first- and second-line drug regimens in resource-poor settings, while darunavir is considered an important second-line treatment option.
“The rejection of the patents on tenofovir opens up the market for new generic competitors to drive down the price of this key AIDS drug,” said Michelle Childs, of the international medical charity, Médecins Sans Frontières. “The decision regarding darunavir is significant because the drug is one of the newest and most expensive of HIV/AIDS drugs.”
Not out of the woods yet
Yet activists warn that the battle is not yet won; Gilead has similar patent applications pending in India, and Novartis, a large Swiss pharmaceutical manufacturer, is going to the Indian Supreme Court to challenge the interpretation and application of “efficacy” by Indian courts and the patent office.
A previous attempt by Novartis to challenge Section 3(d) of India’s Patents Act, 1970, was rejected by the Madras High Court in August 2007.
“India has led the way in provision of affordable medicines to people in the developing world; we encourage them to keep putting their foot down and standing up to big pharmaceutical companies,” said Leonard Okello, a Ugandan AIDS activist and former head of the international HIV team at the anti-poverty NGO, ActionAid.
This feature is used with permission from IRIN/PlusNews – www.plusnews.org
Author
-
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
View all posts
Republish this article

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
India rejects ARV patent applications, saving “countless lives”
by Health-e News, Health-e News
September 7, 2009
MOST READ
Tembisa hospital open to the public, cause of fire under investigation
Gauteng Health’s cost-cutting measures could leave patients waiting over 4 months for care
Tembisa Hospital closed to new patients following emergency unit fire
Eastern Cape Health struggles to repair weather-damaged facilities
EDITOR'S PICKS
Related



Pit toilets in South Africa’s schools will be there long after March 31 deadline


